Roivant Sciences (ROIV) Competitors $11.31 -0.05 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.04 -0.28 (-2.43%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ROIV vs. BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, and ASNDShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. Its Competitors BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories QIAGEN Viatris Ascendis Pharma A/S Roivant Sciences (NASDAQ:ROIV) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Is ROIV or BNTX more profitable? BioNTech has a net margin of -27.37% compared to Roivant Sciences' net margin of -225.71%. BioNTech's return on equity of -3.94% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-225.71% -14.76% -13.69% BioNTech -27.37%-3.94%-3.41% Which has stronger valuation and earnings, ROIV or BNTX? Roivant Sciences has higher earnings, but lower revenue than BioNTech. Roivant Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M264.64-$171.98M-$0.25-45.24BioNTech$2.98B8.67-$719.92M-$3.40-31.57 Does the media refer more to ROIV or BNTX? In the previous week, BioNTech had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for BioNTech and 3 mentions for Roivant Sciences. BioNTech's average media sentiment score of 0.85 beat Roivant Sciences' score of 0.66 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ROIV or BNTX? Roivant Sciences presently has a consensus price target of $16.50, suggesting a potential upside of 45.89%. BioNTech has a consensus price target of $136.58, suggesting a potential upside of 27.24%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Do institutionals and insiders have more ownership in ROIV or BNTX? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ROIV or BNTX? Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. SummaryBioNTech beats Roivant Sciences on 10 of the 17 factors compared between the two stocks. Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.72B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-45.2417.6228.6723.80Price / Sales264.64179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book1.528.508.275.55Net Income-$171.98M-$55.06M$3.24B$259.03M7 Day Performance-2.08%-3.98%-3.69%-4.59%1 Month Performance3.10%9.59%4.33%4.46%1 Year Performance7.61%6.72%25.95%18.03% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences1.8472 of 5 stars$11.31-0.4%$16.50+45.9%+6.5%$7.72B$29.05M-45.24860Upcoming EarningsBNTXBioNTech2.7516 of 5 stars$112.79-2.2%$136.58+21.1%+33.0%$27.72B$2.98B-33.176,772Upcoming EarningsGap DownSMMTSummit Therapeutics3.0125 of 5 stars$27.45-4.3%$34.67+26.3%+153.9%$21.29B$700K-80.73110Upcoming EarningsINSMInsmed3.784 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.72B$363.71M-17.101,271Upcoming EarningsTEVATeva Pharmaceutical Industries3.9835 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.97B$16.54B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6799 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$15.01B$3.12B13.122,682News CoverageUpcoming EarningsShort Interest ↑MRNAModerna4.4709 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeRDYDr. Reddy's Laboratories1.9721 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.25B$3.81B22.2827,811QGENQIAGEN3.3183 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$1.98B127.875,765News CoverageUpcoming EarningsVTRSViatris2.227 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$11.04B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0931 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.24B$393.54M-26.141,017Analyst Forecast Related Companies and Tools Related Companies BNTX Competitors SMMT Competitors INSM Competitors TEVA Competitors GMAB Competitors MRNA Competitors RDY Competitors QGEN Competitors VTRS Competitors ASND Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ROIV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
